HomepageMedicineSustainability and Progress Continue to Make Headlines in 2024 Medicine Sustainability and Progress Continue to Make Headlines in 2024 admin Posted on February 14, 2024 Recognition of the business case for ESG in pharma is soaring. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous Post8 Pet Friendly Hotels in Gatlinburg, TN (2024 Update) Next PostWatchmakers Have a Love-Hate Relationship With Tantalum You Might Also Like Medicine FDA Grants Accelerated Approval to Amgen’s Imdelltra for the Treatment of Adults with Extensive-Stage Small Cell Lung Cancer admin May 19, 2024 Medicine Pharma Pulse 11/1/24: Navigating Diversity and Digital Innovation, Key Clinical Information on Infertility & more admin November 3, 2024 Medicine FDA Grants Full Approval to Johnson & Johnson’s Sirturo for Pulmonary Tuberculosis Caused by Mycobacterium Tuberculosis Resistant to Rifampicin and Isoniazid admin July 9, 2024 Medicine Gilead's Lenacapavir Reduces HIV Infections by 96%, Surpassing Truvada in Twice-Yearly PrEP Treatment admin September 14, 2024
Medicine FDA Grants Accelerated Approval to Amgen’s Imdelltra for the Treatment of Adults with Extensive-Stage Small Cell Lung Cancer admin May 19, 2024
Medicine Pharma Pulse 11/1/24: Navigating Diversity and Digital Innovation, Key Clinical Information on Infertility & more admin November 3, 2024
Medicine FDA Grants Full Approval to Johnson & Johnson’s Sirturo for Pulmonary Tuberculosis Caused by Mycobacterium Tuberculosis Resistant to Rifampicin and Isoniazid admin July 9, 2024
Medicine Gilead's Lenacapavir Reduces HIV Infections by 96%, Surpassing Truvada in Twice-Yearly PrEP Treatment admin September 14, 2024